Drug intelligence / Profile preview

BIM-28125

Development stage: Preclinical
Lead developer: Ipsen
Modality: Peptides
Administration: Subcutaneous

Overview

BIM-28125 is a peptide analogue of ghrelin, used in research for its potential in treating conditions like cardiac cachexia and chronic kidney disease. It acts by binding to the ghrelin receptor (GHS-1a) with higher affinity and potency than native ghrelin, promoting increased food intake and weight gain[1][2][3]. **Mechanism of Action**: - BIM-28125 increases food intake and improves lean body mass. - It regulates the expression of muscle atrophy-related genes like MuRF-1 and MAFbx.

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on BIM-28125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIM-28125.

Explore the full profile